

1 **Oxytocin reduces top-down control of attention by increasing bottom-up attention allocation to**
2 **social but not non-social stimuli**

3

4 **Xiaolei Xu^{a,*}, Jialin Li^{a,*}, Zhuo Chen^a, Keith M. Kendrick^a, Benjamin Becker^a**

5

6 ^aThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory for
7 NeuroInformation, University of Electronic Science and Technology of China, Chengdu, Sichuan
8 610054, China

9

10

11 ***equal contributions**

12

13 **Correspondence to:**

14 Benjamin Becker or Keith M. Kendrick

15 University of Electronic Science and Technology of China

16 The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Laboratory of Neuroinformation

17 No.2006, Xiyuan Ave., West Hi-Tech Zone, Chengdu, Sichuan 611731, China

18 e-mail: ben_becker@gmx.de or k.kendrick.uestc@gmail.com

19

20 **Abstract**

21 The neuropeptide oxytocin (OXT) may facilitate attention to social stimuli by influencing early stage
22 bottom-up processing although findings in relation to different emotional expressions are inconsistent
23 and its influence on top-down cognitive processing mechanisms unclear. In the current double-blind,
24 placebo (PLC) controlled, between subject design study we therefore recruited 71 male subjects to
25 investigate the effects of intranasal OXT (24IU) on both bottom-up attention allocation and top-down
26 attention inhibition using a visual antisaccade paradigm with concurrent eye movement acquisition.
27 Our results show that OXT increased antisaccade errors for social stimuli (all types of emotional
28 faces), but not shapes. This effect of OXT was modulated by trait behavioral inhibition and there was
29 also evidence for reduced state anxiety after OXT treatment. Antisaccades are under volitional control
30 and therefore this indicates that OXT treatment produced reduced top-down inhibition. However, the
31 overall findings are consistent with OXT acting to reduce top-down control of attention as a result of
32 increasing bottom-up early attentional processing of social, but not non-social, stimuli in situations
33 where the two systems are in potential conflict. This effect of OXT is also modulated by individual
34 levels of trait behavioral inhibition possibly as a result of an anxiolytic action.

35

36 **Key words:** attention, cognitive control, emotion, social salience, oxytocin, eye gaze

37

38

39 **1. Introduction**

40 The neuropeptide oxytocin (OXT) has been repeatedly demonstrated to facilitate early attentional
41 processing of socio-emotional stimuli which may promote facial emotion recognition (Domes et al.,
42 2007; Guastella et al., 2010; Luo et al., 2017). Specifically, the intranasal administration of OXT has
43 been found to increase attention to the eye region (Guastella et al, 2008), to enhance detection of
44 emotions in subliminal presented backward-masked facial stimuli (Schulze et al., 2011) and to
45 augment early attentional orientation towards facial stimuli (Domes et al., 2013; Tollenaar et al.,
46 2013; Xu et al., 2015). Depending on the specific task paradigms employed, OXT has been found to
47 enhance attentional bias towards positive (Domes et al., 2013), positive and neutral (Xu et al., 2015),
48 or positive and negative (Tollenaar et al., 2013) social stimuli. In another study OXT was found to
49 promote switching of attention away from internal interoceptive cues towards external social ones
50 (positive, negative or neutral expression faces) (Yao et al., 2018). Together, these findings suggest a
51 role for OXT in automatic, bottom-up attention processing of salient social-emotional stimuli.
52 However, attention is a strongly limited cognitive resource and efficient allocation of this resource
53 requires a balanced interplay between stimulus-driven bottom-up orientation towards salient stimuli in
54 the environment and top-down goal-directed cognitive control of attention in response to task
55 demands (Buschman and Miller 2007; Corbetta et al., 2008). Despite an initial report on the
56 modulatory influence of intranasal OXT on cognitive control during processing of non-social salient
57 stimuli (Striepens et al., 2016), to date differential effects of OXT on bottom-up versus top-down
58 control of attention towards social versus non-social stimuli have not been examined. Against this

59 background the current study combined a randomized double-blind placebo controlled OXT
60 administration protocol with an antisaccade eye-tracking paradigm to determine OXT effects on both
61 bottom-up stimulus-driven attention (prosaccade) and top-down inhibitory control of attention
62 (antisaccade).

63 Antisaccade paradigms have been widely employed to investigate top-down (volitional)
64 inhibitory control of attention in response to task demands. Briefly, a stimulus is presented in the
65 peripheral region of the visual field and subjects are instructed to either look towards (prosaccade) or
66 away from (antisaccade) the stimulus. The prosaccade eye gaze represents a stimulus-driven reflexive
67 behavioral response towards a potentially salient stimulus in the environment. In contrast, a successful
68 antisaccade requires the initial inhibition of the stimulus-driven automatic prosaccade as well as the
69 subsequent volitional saccade away from the distractors, reflecting a top-down inhibitory attentional
70 control mechanism (Munoz and Everling, 2004).

71 In view of frequently reported social-specific effects of OXT (Shamay-Tsoory and Abu-Akel,
72 2016) the present study employed a social-emotional antisaccade paradigm including neutral, happy,
73 sad, fearful and angry facial expressions as social and oval shapes as non-social stimuli to determine
74 whether OXT generally modulates attention allocation or specifically modulates the processing of
75 social stimuli. Moreover, given previous reports on valence-specific effects of OXT on processing of
76 social stimuli (Xu et al., 2015), stimuli of different facial emotions were included to allowed to further
77 explore emotion-specific effects of OXT on social attention allocation. Given that overarching
78 hypotheses on the modulatory influence of OXT on social cognition suggest that its augmentation of
79 social salience represents a core mechanism of action across different functional domains

80 (Shamay-Tsoory and Abu-Akel, 2016) we hypothesized that OXT would specifically increase
81 attentional bias for social stimuli as reflected by facilitated prosaccades in the context of impaired
82 inhibition of volitional attentional control (impaired antisaccades). Based on our previous findings
83 suggesting that OXT specifically enhances attention allocation towards neutral and positive facial
84 stimuli (Domes et al., 2013; Xu et al., 2015) we further hypothesized that OXT would particularly
85 affect processing of neutral and positive (happy) faces rather than that of negative ones such as sad,
86 fearful, and angry faces.

87

88 **2. Materials and methods**

89 **2.1 Participants**

90 71 healthy male students aged 18-30 years (mean \pm sem = 21.85 \pm 0.32 years) from the University of
91 Electronic Science and Technology of China (UESTC) were recruited for the present randomized,
92 placebo-controlled, double blind between-subject pharmacological eye tracking study. Exclusion criteria
93 were any previous or current neurological or psychiatric disorders, as well as current (30 days before
94 the experiment) or regular use of any psychotropic substances, including nicotine. All participants
95 were instructed to abstain from alcohol and caffeine during the 24 hours before the pharmacological
96 eye-tracking experiment. Participants were randomly assigned to receive either 24 International Units
97 (IU) of intranasal OXT (n = 34, mean \pm sem age = 21.88 \pm 0.44 years) or placebo (PLC, n = 37, mean
98 \pm sem age = 21.81 \pm 0.46 years).

99 Study protocols had full approval by the local ethics committee at the UESTC and experimental
100 in accordance with the latest revision of the Declaration of Helsinki. All participants provided

101 informed consent before the experiment and received monetary compensation for participation. Study
102 protocols and primary outcomes were pre-registered at clinical trials.gov
103 (<https://clinicaltrials.gov/ct2/show/NCT03486925>, Trial ID: NCT03486925).

104

105 **2.2 Experimental protocols and procedures**

106 To control for confounding effects of between-group differences in variables that have previously
107 been demonstrated to modulate the effects of intranasal OXT (Kendrick et al., 2017) potential
108 confounders were assessed before treatment administration by means of validated scales. Based on
109 previous findings suggesting that individual variations in these variables modulate the effects of OXT,
110 the following variables were assessed: childhood maltreatment (Childhood Trauma Questionnaire,
111 CTQ) (Bernstein and Fink, 1998), social anxiety (Liebowitz Social Anxiety Scale, LSAS; Social
112 Interaction Anxiety Scale, SIAS) (Mattick and Clarke, 1998; Heimberg et al., 1999), state anxiety
113 (State-Trait Anxiety Inventory, STAI) (Barnes et al., 2002), depressive symptom load (Beck
114 Depression Inventory, BDI-II) (Beck et al., 1996), autism traits (the Adult Autism Spectrum Quotient,
115 ASQ) (Baron-Cohen et al., 2001) and mood (Positive and Negative Affect Schedule, PANAS)
116 (Watson and Clark, 1988). In line with the focus of the study on cognitive control towards emotional
117 stimuli, additional scales included the Action Control Scale (ACS) (Kuhl, 1994), Behavioral
118 Inhibition System and Behavioral Activation System Scale (BIS/BAS) (Charles and White, 1994) and
119 Emotion Regulation Questionnaire (ERQ) (Wang et al., 2015). Next, participants self-administrated
120 either 24 IU of OXT (Oxytocin-spray, Sichuan Meike Pharmaceutical Co., Ltd; 3 puffs of 4IU per
121 nostril with 30s between each puff) or PLC (PLC – identical sprays with the same ingredients other

122 than OXT). Administration adhered to standardized intranasal OXT protocols (Guastella et al., 2013),
123 and in line with the pharmacodynamics of intranasal OXT in humans (Spengler et al., 2017) treatment
124 was administered 45 minutes before the eye-tracking paradigm. Mood (PANAS) and state anxiety
125 (STAI-S) were additionally assessed after the experiment to control for unspecific effects of treatment
126 on these domains.

127 Individual differences in the behavioral inhibition system (BIS) have been associated with both,
128 attentional processing and top-down control of orientation towards social-emotional stimuli, including
129 antisaccade performance (Dennis and Chen, 2009; Mogg et al., 2012). To determine whether OXT
130 affects this association, correlations between individual variations in behavioral inhibition and eye
131 gaze indices that showed OXT effects were further examined within the treatment groups.


132

133 **2.3 Antisaccade paradigm**

134 We employed a modified antisaccade paradigm (Chen et al., 2014) that included 5 social-emotional
135 conditions (facial expressions from 4 male and 4 female actors: neutral, happy, fearful, sad, angry
136 expressions) and a non-social control condition (oval shape, the shape was slightly varied to create 8
137 different shape stimuli). A total of 576 trials over 14 blocks were presented including 2 non-social
138 control blocks (one anti- and one pro-saccade block) and 12 emotional blocks (6 anti- and 6
139 pro-saccade blocks). Each emotional block contained 40 trials in randomized order including 8 trials
140 per emotional condition resulting in 48 trials in total per anti- and pro-saccade condition respectively.
141 To avoid carry-over of emotion-specific effects of OXT the paradigm started with the shape blocks,
142 which also contained 48 trials, followed by the emotional blocks. The order of anti- and pro-saccade

143 blocks was randomized. Each block started with a 2000ms visual instruction (“Towards”, “Away”)
144 indicating whether the subsequent block required a pro- or an anti-saccade response followed by a
145 jittered fixation cross (1000-3500ms; mean duration = 1500ms). Following the fixation period a
146 stimulus was presented at 8° visual angle relative to the centered fixation cross to the left or right
147 visual field for 1000ms. The size of stimuli was 400×500 pixels. Participants were asked to direct
148 their gaze as fast as possible towards the stimulus during the prosaccade (“Towards”) blocks and
149 away from it in the opposite direction during the antisaccade (“Away”) (Fig 1).

150



159 **Figure 1** Each block started with an instruction indicating whether a prosaccade (“Towards”) or an
160 antisaccade (“Away”) response was required, followed by a fixation cross centered on the screen. A
161 stimulus was presented at the left or right peripheral position after the fixation disappeared. For
162 “Towards” blocks, subjects were asked to look at the stimulus (prosaccade) and for “Away” blocks
163 they were instructed to look away from the stimulus to the opposite position (antisaccade).

164

165 Subjects completed the experiment in a dimly illuminated room. Stimuli were presented on a
166 17inch monitor at a resolution of 1024×768 pixels. A chin rest was used to standardize the distance

167 and position from the screen (57cm away and centrally positioned relative to the monitor). The eye
168 gaze data was acquired using an EyeLink 1000 Plus system (SR Research, Ottawa, Canada) in
169 monocular mode at a sampling rate of 2000Hz. Before each block a 9-point calibration was conducted,
170 the experimental blocks were divided by brief rest periods to facilitate attentive processing throughout
171 the experiment. For the subsequent analyses saccades were excluded based on the criteria of
172 amplitude $< 1.5^\circ$, velocity $< 30^\circ/\text{sec}$, and latencies shorter than 80ms which were classified as
173 anticipatory saccades (for a similar strategy see Wieser et al., 2009). The number of excluded
174 anticipatory saccades did not differ between the treatment groups ($p = 0.23$). The raw eye gaze data
175 was initially exported and processed using the EyeLink DataViewer 3.1 (SR Research, Mississauga,
176 Ontario, Canada) and effects of treatment were subsequently analyzed using SPSS 18.0 software
177 (SPSS Inc., Chicago, Illinois, USA).


178 Mean error rates for pro- and anti-saccade blocks and latencies for correct saccades served as
179 primary outcomes to determine effects of treatment. Mixed ANOVA models and independent sample
180 t-tests were employed to determine differences between the treatment groups. Post-hoc tests
181 incorporated Bonferroni correction for multiple comparisons. Associations between individual
182 variations in pre-treatment behavioral inhibition (BIS score) and eye gaze behavior were examined
183 using Pearson correlation and differences in the correlations between the two treatment groups were
184 assessed by Fisher' Z test with appropriate Bonferroni correction.

185

186 **3. Results**

187 **3.1 Potential confounders**

188 Examining the pre-treatment data on potential confounders using independent t-tests did not reveal
189 significant differences between the two treatment groups (details see Table 1). Likewise, no
190 significant post-treatment differences between the treatment groups were observed for mood. Together,
191 these findings argue against potential confounding effects of pre-treatment differences or unspecific
192 treatment effects. While there were no significant post-treatment differences between the PLC and
193 OXT groups for state-anxiety ($p = 0.07$) there was a significant reduction in state anxiety in the OXT
194 group when comparing pre vs post-treatment scores ($p = 0.027$), but not in the PLC group ($p = 0.882$,
195 **Fig 2**). This suggests that OXT treatment produced anxiolytic effects within the group treated with
196 OXT.



197
198 **Figure 2** State anxiety (SAI) scores assessed by State-Trait Anxiety Inventory (STAI) before and after
199 treatment. OXT significantly decreased state anxiety after the experiment within the oxytocin-
200 treatment group. Abbreviations: PLC, placebo, OXT, oxytocin

201


202 3.2 Eye-tracking data

203 Eye movement data from 4 subjects were excluded based on the quality assessment criteria (see
204 methods, also Wieser et al., 2009) leading to a final sample of PLC = 33 and OXT = 34 for the eye
205 gaze data analyses.

206

207 3.2.1 Saccade latency

208 A 2 (treatment: OXT/PLC) × 2 (stimuli: non-social shape/social-face) × 2 (task: anti-/pro-saccade)
209 mixed ANOVA was conducted to examine saccade latencies. Results revealed significant main effects
210 of task ($F_{1,65} = 819.57, p < 0.001, \eta^2_p = 0.93$) and stimuli ($F_{1,65} = 77.14, p < 0.001, \eta^2_p = 0.54$), as well as a
211 significant stimuli × treatment ($F_{1,65} = 4.66, p = 0.035, \eta^2_p = 0.07$) and stimuli × task ($F_{1,65} = 64.84,$
212 $p < 0.001, \eta^2_p = 0.50$) interaction effects. Post-hoc Bonferroni-corrected paired comparisons indicated
213 that the antisaccade latency was significantly longer than the prosaccade one (antisaccade: mean±sem
214 = 277.71±3.33ms, prosaccade: mean±sem = 192.74±2.04ms, $p < 0.001$, Cohen's $d = 3.23$) and that
215 saccades for social-face stimuli were generally faster than those for shape stimuli (non-social, shape,
216 mean±sem = 242.98±2.74ms; social, face stimuli, mean±sem = 227.47±2.21ms, $p < 0.001$, Cohen's $d =$
217 0.31). Examining the stimuli × treatment interaction effect revealed that saccades for the social-face
218 stimuli were faster in both treatment groups (PLC: non-social, shape, mean±sem = 245.83±3.91ms,
219 social, face stimuli, mean±sem = 226.51±3.15ms, $p < 0.001$, Cohen's $d = 0.82$; OXT: non-social, shape,
220 mean±sem = 240.12±3.85ms, social, face stimuli, mean±sem = 228.43±3.11ms, $p < 0.001$, Cohen's $d =$
221 0.49; **Fig 3**). Specifically, longer saccade latencies for the shapes were observed during prosaccade
222 but not antisaccade blocks (antisaccade: non-social, shape = 279.28±3.74ms, social, face stimuli =
223 276.13±3.47ms; $p = 0.258$, Cohen's $d = 0.10$; prosaccade: non-social, shape = 206.67±2.60ms, social,
224 face stimuli = 178.81±1.78ms, $p < 0.001$, Cohen's $d = 1.55$). Together the results indicate that task
225 instruction (pro- versus anti-saccade) and stimuli (social vs non-social) successfully modulated the
226 behavioral response during the paradigm.



227

228 **Figure 3** Saccade latencies for shape and face stimuli in the placebo and oxytocin treated group
229 respectively. Abbreviations: PLC, placebo, OXT, oxytocin

230

231 3.2.2 Saccade error rate

232 A 2 (treatment: OXT/PLC) × 2 (stimuli: non-social shape/social-face) × 2 (task: anti-/pro-saccade)

233 mixed ANOVA was carried out including saccade error rates as dependent variable. Results revealed

234 significant main effects of stimuli ($F_{1,65} = 21.87, p < 0.001, \eta^2_p = 0.25$), task ($F_{1,65} = 112.16, p < 0.001,$

235 $\eta^2_p = 0.63$), and treatment ($F_{1,65} = 8.88, p = 0.004, \eta^2_p = 0.12$) as well as significant task × treatment

236 ($F_{1,65} = 4.67, p = 0.034, \eta^2_p = 0.067$) and task × stimuli ($F_{1,65} = 8.15, p = 0.006, \eta^2_p = 0.11$) interaction

237 effects. Post-hoc Bonferroni-corrected comparisons demonstrated that the error rate for shapes was

238 significantly lower compared to social-face stimuli (non-social, shape: mean±sem = 15.53%±1.19,

239 social, face stimuli: mean±sem = 20.40%±1.20, $p < 0.001$, Cohen's $d = 0.39$) and the error rate for

240 antisaccades was significantly higher compared to prosaccades (antisaccade: mean±sem =

241 22.92%±1.25%, prosaccade: mean±sem = 13.01%±1.09, $p < 0.001$, Cohen's $d = 0.84$). Overall, OXT


242 significantly increased the error rate compared to PLC (PLC: mean±sem = 14.75%±1.54, OXT:

243 mean±sem = 21.18%±1.51, $p = 0.004$, Cohen's $d = 0.59$). In addition, there was a marginal significant

244 three-way treatment × stimuli × task interaction effect ($F_{1,65} = 3.03, p = 0.086, \eta^2_p = 0.045$) and

245 exploratory analyses revealed that OXT specifically increased error rates for antisaccades of social
246 face stimuli (antisaccade: social, face stimuli: PLC = 20.78%±2.09, OXT = 32.35%±2.06, $t = 3.94$,
247 $p < 0.001$, Cohen's $d = 0.97$, **Fig 4a**).

248 To further explore potential emotion-specific effects of OXT on antisaccade performance an
249 additional 2 (treatment: OXT/PLC) × 6 (stimuli-emotions: shape/happy/angry/neutral/sad/fear) mixed
250 ANOVA with antisaccade error rates as dependent variable was performed. Results revealed a main
251 effect of stimuli ($F_{5,325} = 10.52$, $p < 0.001$, $\eta^2_p = 0.14$, error rate of shape is significantly lower than all
252 emotional conditions, all $ps < 0.02$) and treatment ($F_{1,65} = 15.30$, $p < 0.001$, $\eta^2_p = 0.19$) suggesting that
253 OXT significantly increased antisaccade error rates compared to PLC (PLC = 20.09%±1.92, OXT =
254 30.62%±1.89, Cohen's $d = 0.80$, $p < 0.001$). A marginal significant drug × stimuli interaction effect
255 ($F_{1,325} = 2.01$, $p = 0.077$, $\eta^2_p = 0.03$) and post-hoc exploratory analysis further revealed that OXT
256 significantly increased the error rates for the all social stimuli but not the shape stimuli (OXT vs. PLC,
257 for all face emotion conditions $ps < 0.002$, shape $p = 0.09$, effect size for the social-emotion specific
258 post-hoc comparisons: angry: Cohen's $d = 0.83$; fearful: Cohen's $d = 0.78$; happy: Cohen's $d = 0.87$;
259 neutral: Cohen's $d = 0.81$; sad: Cohen's $d = 1.09$; shape: Cohen's $d = 0.43$, **Fig 4b**).



260
261 **Figure 4** (a) Oxytocin increases the error rate in the social face but not the shape condition in

262 antisaccade blocks; (b) Oxytocin generally increases the error rate for each face emotion but not for
263 shapes during antisaccade blocks. $**p < 0.005$ Abbreviations: PLC, placebo, OXT, oxytocin

264

265 3.3 Effects of oxytocin on the associations between eye gaze and trait behavioral inhibition

266 To assess modulatory effects of OXT on the association between individual differences in

267 pre-treatment behavioral inhibition and cognitive control of attention, Pearson correlations between

268 trait inhibition (BIS score) and antisaccade error rates were examined separately in the treatment

269 groups. Correlation analyses revealed that the antisaccade error rate for social stimuli was


270 significantly positively associated with pre-treatment BIS scores following OXT but not PLC (PLC: r

271 $= -0.189$, $p = 0.292$, OXT: $r = 0.397$, $p = 0.022$, correlation difference, Fisher's $Z = -2.368$, $p = 0.018$,

272 Cohen's $q = 0.27$, **Fig 5**). This suggests that OXT particularly blunted the cognitive inhibition of

273 stimulus-driven attention towards social stimuli in subjects with higher levels of trait behavioral

274 inhibition.



275

276 **Figure 5** Trait behavioral inhibition as assessed by the BIS scale was positively associated with the

277 error rates for social stimuli antisaccades following OXT but not in PLC treatment. $*p < 0.05$

278 Abbreviations: PLC, placebo, OXT, oxytocin

279

280 4. Discussion

281 Overall, results from the present pharmacological eye-gaze study employing a social-emotional pro-
282 and anti-saccade paradigm revealed that participants respond to emotional faces faster than to shapes
283 in the prosaccade blocks and are more prone to errors in the antisaccade blocks, indicating that social
284 stimuli capture greater attention and are more difficult to inhibit responses towards. Furthermore,
285 OXT significantly increased the error rate for facial stimuli during the antisaccade but not the
286 prosaccade condition, suggesting that it decreases the ability to switch attention away from social
287 stimuli, but not non-social stimuli compared with PLC treatment. The effect was significantly
288 positively associated with trait behavioral inhibition as assessed by BIS scores in the OXT, but not the
289 PLC group indicating that OXT is particularly decreasing the ability of subjects with higher general
290 levels of behavioral inhibition to switch their attention away from social but not non-social stimuli.

291 Our finding that OXT decreased the ability to switch attention away from emotional faces but not
292 shapes is in line with previous studies reporting that it specifically increased attention towards social
293 (neutral and positive expression faces) but not non-social stimuli in an attentional-blink task (Xu et al.,
294 2015) and enhanced attention towards distracting external social stimuli (all face expressions) in an
295 interoceptive awareness task (Yao et al., 2018). Studies have increasingly demonstrated that OXT
296 plays an important role in attention orientation and attention regulation to social cues (for review:
297 Shamay-Tsoory and Abu-Akel, 2016). Rapid and accurate recognition of others' emotions from their
298 facial expressions is critical for human social interactions (Adolphs, 2002) and OXT has been found
299 to enhance this ability e.g. by increasing attention to the eye region of human faces (Domes et al.,
300 2007; Guastella et al., 2008). The antisaccade gaze requires volitional inhibition of automatic
301 attention allocation towards sudden-onset visual targets and antisaccade performance is strongly

302 modulated by the salience of the stimulus (Myers et al., 2011). The social salience hypothesis of OXT
303 has proposed that OXT is of particular importance for regulating attention towards salient social cues
304 (Shamay-Tsoory and Abu-Akel, 2016). This enhanced social salience effect of OXT might therefore
305 have contributed to an increased difficulty in inhibiting saccades away from facial, but not shape,
306 stimuli, resulting in higher error rates for antisaccadic eye-gaze behavior in the context of social
307 stimuli.

308 Previous studies investigating the effects of OXT on attentional bias towards specific emotions
309 revealed inconsistent findings. Some studies reported that OXT specifically enhanced attention
310 allocation towards neutral or positive facial stimuli (Domes et al., 2013; Xu et al., 2015) while other
311 studies found that it reduced attentional bias towards negative emotion ones (Kim et al., 2014),
312 increased attention orientation to faces expressing either positive and negative emotions (Tollenaar et
313 al., 2013) or all faces irrespective of emotion (Yao et al., 2018). Although we hypothesized on the
314 basis of these previous findings indicating that OXT can influence early attentional processing of
315 salient social stimuli via acting on bottom-up processing, we failed in the current study to find
316 supportive evidence in terms of either reduced latencies or errors rates when subjects made reflexive
317 prosaccades towards face stimuli. One early study on OXT modulation of detection of social stimuli
318 also failed to find evidence for effects on early perceptual stage processing using a visual search task
319 (Guastella et al., 2009). While this might be considered as evidence for the absence of effects of OXT
320 on bottom-up processing it is notable that in the current task prosaccade errors were very few (13%)
321 and latencies very fast as one would expect for a reflexive response. As such, this might represent a

322 ceiling effect leading to a limited sensitivity of the prosaccade condition to capture OXT treatment
323 effects on bottom-up social attention allocation.

324 The robust effect of OXT (>50% increase across face emotions, effect size Cohen's $d= 0.78-1.09$)
325 on increasing antisaccade errors could either be interpreted as evidence for it selectively weakening
326 top-down control processing, without influencing bottom-up control, or alternatively as it increasing
327 bottom-up reflexive mechanisms resulting in impaired top-down control. While OXT only influenced
328 antisaccade and not prosaccade errors, the net effect of this is that subjects under OXT made more
329 prosaccades towards social stimuli so this can be considered as evidence of increased bottom-up
330 processing. On the other hand, top-down attention inhibition is not biased by specific emotions and
331 the effects of OXT on antisaccade errors occurred across all the face emotions. It is clear from
332 previous studies that across different paradigms that OXT often influences bottom-up processing of
333 specific face emotions (Domes et al., 2013; Kim et al., 2013; Tolenaar et al., 2013; Xu et al., 2015)
334 although one study has shown OXT effects irrespective of the specific face emotion (Yao et al., 2018).
335 Interestingly, the latter study showing effects of OXT on bottom up processing across all face
336 emotions was the only one where the paradigm involved potential conflict between top-down and
337 bottom up processing and as such is similar to the antisaccade paradigm. Thus, it is possible that OXT
338 does primarily influence bottom-up attentional processing of salient social stimuli such as faces but
339 whether it alters attention towards specific face expressions or all of them may depend on the extent
340 to which cognitive top-down control and bottom-up reflexive processing mechanisms are in conflict.

341 The behavioral inhibition system inhibits movements towards targets which may lead to negative
342 outcomes and increase negative feelings such as anxiety and nervousness (Carver and White, 1994).

343 In the current study we found that subjects with higher behavioral inhibition as measured by the BIS
344 showed pronounced effects of OXT with respect to increased antisaccade errors. Individuals with
345 higher BIS scores tend also to exhibit higher social anxiety (Kimbrel et al., 2012) which is associated
346 with increasing antisaccade error rates in response to all facial expressions (Wieser et al., 2009).
347 While OXT has generally been associated with anxiolytic effects (see Kendrick et al., 2017) several
348 studies have also reported that it can have anxiogenic ones (Striepens et al., 2012; Grillon et al., 2013).
349 In the present study there was however evidence for a significant decrease rather than increase in state
350 anxiety following OXT, but not PLC, treatment. Thus, it is possible that OXT reduced social anxiety
351 in subjects with higher BIS scores resulting in them being less motivated to avoid looking at social
352 stimuli which in turn may have increased antisaccade error-rates for social stimuli.

353 In conclusion, the current study has demonstrated that OXT may primarily function to increase
354 bottom-up processing of attention to salient social stimuli and that where there is a context of
355 conflicting top-down cognitive processing the influence of the latter over bottom-up processing is
356 weakened, leading to more errors in the cognitive task component. The influence of OXT in this
357 context is modulated by trait behavioral inhibition, possibly as a result of its anxiolytic effects.

358

359 **Funding and disclosure**

360 This work was supported by grants from National Natural Science Foundation of China (NSFC)
361 [91632117; 31530032]; Fundamental Research Funds for the Central Universities [ZYGX2015Z002];
362 Science, Innovation and Technology Department of the Sichuan Province [2018JY0001]. The authors
363 declare no competing interests.

364

365 **References**

- 366 Adolphs, R., 2002. Recognizing emotion from facial expressions: psychological and neurological
367 mechanisms. *Behav Cogn Neurosci Rev.* 1, 21-62.
368 <https://doi.org/10.1177/1534582302001001003>
- 369 Baron-Cohen, S., Wheelwright, S., Skinner, R., Martin, J., Clubley, E., 2001. The Autism Spectrum
370 Quotient : Evidence from Asperger syndrome/high functioning autism, males and females,
371 scientists and mathematicians. *J Autism Dev Disord.* 31, 5-17.
372 <https://doi.org/10.1023/A:1005653411471>
- 373 Barnes, L. L., Harp, D., Jung, W. S., 2002. Reliability generalization of scores on the Spielberger
374 state-trait anxiety inventory. *Educ Psychol Meas.* 62, 603-618.
375 <https://doi.org/10.1177/0013164402062004005>
- 376 Beck, A. T., Steer, R. A., Brown, G. K., 1996. Manual for Beck depression inventory. San Antonio,
377 TX: The Psychological Corporation.
- 378 Bernstein, D. P., Fink, L., 1998. Childhood trauma questionnaire: A retrospective self-report: Manual.
379 San Antonio, TX: The Psychological Corporation.
- 380 Buschman TJ, M. E., 2007. Top-down versus bottom-up control of attention in the prefrontal and
381 posterior parietal cortices. *Science.* 315, 1860-1862. <https://doi.org/10.1126/science.1138071>
- 382 Carver, C. S., White, T. L., 1994. Behavioral inhibition, behavioral activation, and affective responses
383 to impending reward and punishment: the BIS/BAS scales. *J Pers Soc Psychol.* 67, 319.
- 384 Chen, N. T. M., Clarke, P. J. F., Watson, T. L., MacLeod, C., Guastella, A. J., 2014. Biased saccadic
385 responses to emotional stimuli in anxiety: An antisaccade study. *PLoS One*, 9, e86474.

386 <https://doi.org/10.1371/journal.pone.0086474>

387 Corbetta, M., Patel, G., Shulman, G. L., 2008. The reorienting system of the human brain: from
388 environment to theory of mind. *Neuron*. 58, 306–324.

389 <https://doi.org/10.1016/j.neuron.2008.04.017>

390 Dennis, T. A., Chen, C., 2009. Neurophysiological mechanisms in the emotional modulation of
391 attention: The interplay between threat sensitivity and attentional control, *Biol Psychol*. 76, 1–10.

392 <https://doi.org/10.1016/j.biopsycho.2007.05.001>

393 Domes, G., Heinrichs, M., Michel, A., Berger, C., Herpertz, S. C., 2007. Oxytocin Improves
394 “Mind-Reading” in Humans. *Biol Psychiatry*. 61, 731–733.

395 <https://doi.org/10.1016/j.biopsych.2006.07.015>

396 Domes, G., Sibold, M., Schulze, L., Lischke, A., Herpertz, S. C., Heinrichs, M., 2013. Intranasal
397 oxytocin increases covert attention to positive social cues. *Psychol Med*. 43, 1747–1753.

398 <https://doi.org/10.1017/S0033291712002565>

399 Domes, G., Steiner, A., Porges, S. W., Heinrichs, M., 2013. Oxytocin differentially modulates eye
400 gaze to naturalistic social signals of happiness and anger. *Psychoneuroendocrinology*. 38,

401 1198–1202. <https://doi.org/10.1016/j.psyneuen.2012.10.002>

402 Grillon, C., Krinsky, M., Charney, D. R., Vytal, K., Ernst, M., Cornwell, B., 2013. Oxytocin
403 increases anxiety to unpredictable threat. *Mol Psychiatry*. 18, 958–960.

404 <https://doi.org/10.1038/mp.2012.156>

405 Guastella, A. J., Carson, D. S., Dadds, M. R., Mitchell, P. B., Cox, R. E., 2009. Does oxytocin

406 influence the early detection of angry and happy faces? *Psychoneuroendocrinology*. 34, 220–225.

- 407 <https://doi.org/10.1016/j.psychneuen.2008.09.001>
- 408 Guastella, A. J., Einfeld, S. L., Gray, K. M., Rinehart, N. J., Tonge, B. J., Lambert, T. J., Hickie, I. B.
409 (2010). Intranasal Oxytocin Improves Emotion Recognition for Youth with Autism Spectrum
410 Disorders. *Biol Psychiatry*. 67, 692–694. <https://doi.org/10.1016/j.biopsych.2009.09.020>
- 411 Guastella, A. J., Mitchell, P. B., Dadds, M. R., 2008. Oxytocin Increases Gaze to the Eye Region of
412 Human Faces. *Biol Psychiatry*. 63, 3–5. <https://doi.org/10.1016/j.biopsych.2007.06.026>
- 413 Guastella, A. J., Hickie, I. B., McGuinness, M. M., Otis, M., Woods, E. A., Disinger, H. M., Chan, H.
414 K., Chen, T. F., Banati, R. B., 2013. Recommendations for the standardisation of oxytocin nasal
415 administration and guidelines for its reporting in human research. *Psychoneuroendocrinology*. 38,
416 612–625. <https://doi.org/10.1016/j.biopsych.2009.09.020>
- 417 Heimberg, R. G., Horner, K. J., Juster, H. R., Safren, S. A., Brown, E. J., Schneier, F. R., Liebowitz,
418 M. R., 1999. Psychometric properties of the Liebowitz social anxiety scale. *Psychol Med*. 29,
419 199-212. <https://doi.org/10.1017/S0033291798007879>
- 420 Hutton, S. B., Ettinger, U., 2006. The antisaccade task as a research tool in psychopathology: A
421 critical review. *Psychophysiology*. 43, 302–313.
422 <https://doi.org/10.1111/j.1469-8986.2006.00403.x>
- 423 Kendrick K.M., Guastella A.J., Becker B., 2017. Overview of Human Oxytocin Research. In:
424 Hurlemann R., Grinevich V. (eds) *Behavioral Pharmacology of Neuropeptides: Oxytocin*.
425 *Current Topics in Behavioral Neurosciences*, vol 35. Springer, Cham
- 426 Kim, Y. R., Oh, S. M., Corfield, F., Jeong, D. W., Jang, E. Y., Treasure, J., 2014. Intranasal oxytocin
427 lessens the attentional bias to adult negative faces: A double blind within-subject experiment.

- 428 [Psychiatry Investig.](https://doi.org/10.4306/pi.2014.11.2.160) 11, 160–166. <https://doi.org/10.4306/pi.2014.11.2.160>
- 429 Kimbrel, N. A., Nelson-gray, R. O., Mitchell, J. T., 2012. BIS, BAS, and Bias : The Role of
430 Personality and Cognitive Bias in Social Anxiety. *Pers Individ Dif.* 52, 395–400.
431 <https://doi.org/10.1016/j.paid.2011.10.041>
- 432 Kuhl, J., 1994. Action versus state orientation: Psychometric properties of the Action Control Scale
433 (ACS-90). *Volition and personality: Action versus state orientation.* 47, 56.
- 434 Luo L, Becker B, Geng Y, Zhao Z, Gao S, Zhao W, Yao S, Zheng X, Ma X, Zhao G, Hu J, Kendrick,
435 K. M., 2017. The sex-dependent effect of oxytocin to masked negative faces: associations with
436 anxiety. *Neuroimage.* 162, 127-137. <https://doi.org/10.1016/j.neuroimage.2017.08.079>
- 437 Mattick, R. P., Clarke, J. C., 1998. Development and validation of measures of social phobia scrutiny
438 fear and social interaction anxiety. [Behav Res Ther.](https://doi.org/10.1016/j.brat.1998.05.001) 36, 455–470.
- 439 Reinholdt-Dunne, M. L., Mogg, K., Benson, V., Bradley, B. P., Hardin, M. G., Liversedge, S. P.,
440 Liversedge, D. S., Ernst, M., 2012. Anxiety and selective attention to angry faces: An
441 antisaccade study. *J Cogn Psychol.* 24, 54-65. <https://doi.org/10.1080/20445911.2011.560111>
- 442 Munoz, D. P., Everling, S., 2004. Look away: The anti-saccade task and the voluntary control of eye
443 movement. *Nat Rev Neurosci.* 5, 218–228. <https://doi.org/10.1038/nrn1345>
- 444 Myers, C. W., Gray, W. D., Sims, C. R., 2011. The insistence of vision: Why do people look at a
445 salient stimulus when it signals target absence? *Vis cogn.* 19, 1122–1157.
446 <https://doi.org/10.1080/13506285.2011.614379>
- 447 Schulze, L., Lischke, A., Greif, J., Herpertz, S. C., Heinrichs, M., Domes, G., 2011. Oxytocin
448 increases recognition of masked emotional faces. *Psychoneuroendocrinology.* 36, 1378–1382.

- 449 <https://doi.org/10.1016/j.psyneuen.2011.03.011>
- 450 Shamay-Tsoory, S. G., Abu-Akel, A., 2016. The Social Salience Hypothesis of Oxytocin. *Biol*
- 451 *Psychiatry*. 79, 194–202. <https://doi.org/10.1016/j.biopsych.2015.07.020>
- 452 Spengler, F. B., Schultz, J., Scheele, D., Essel, M., Maier, W., Heinrichs, M., Hurlmann, R., 2017.
- 453 Kinetics and Dose Dependency of Intranasal Oxytocin Effects on Amygdala Reactivity. *Biol*
- 454 *Psychiatry*. 82, 885–894. <https://doi.org/10.1016/j.biopsych.2017.04.015>
- 455 Striepens, N., Scheele, D., Kendrick, K. M., Becker, B., Schäfer, L., Schwalba, K., Reul, J., Maier, W.,
- 456 Hurlmann, R., 2012. Oxytocin facilitates protective responses to aversive social stimuli in males.
- 457 *Proc. Natl. Acad. Sci. U. S. A.* 109, 18144–18149. <https://doi.org/10.1073/pnas.1208852109>
- 458 Striepens N, Schröter F, Stoffel-Wagner B, Maier W, Hurlmann R, S. D., 2016. Oxytocin enhances
- 459 cognitive control of food craving in women. *Hum Brain Mapp*. 37, 4276–4285.
- 460 <https://doi.org/10.1002/hbm.23308>
- 461 Tollenaar, M. S., Chatzimanoli, M., van der Wee, N. J. A., Putman, P., 2013. Enhanced orienting of
- 462 attention in response to emotional gaze cues after oxytocin administration in healthy young men.
- 463 *Psychoneuroendocrinology*. 38, 1797–1802. <https://doi.org/10.1016/j.psyneuen.2013.02.018>
- 464 Wang, F., Wang, C., Yin, Q., Wang, K., Li, D., 2015. Reappraisal writing relieves social anxiety and
- 465 may be accompanied by changes in frontal alpha asymmetry. *Front Psychol*. 6, 1604.
- 466 <https://doi.org/10.3389/fpsyg.2015.01604>
- 467 Watson, D., Clark, L. A., Tellegen, A., 1988. Development and validation of brief measures of
- 468 positive and negative affect: the PANAS scales. *J Pers Soc Psychol*. 54, 1063.
- 469 Wieser, M. J., Pauli, P., Mühlberger, A., 2009. Probing the attentional control theory in social anxiety:

470 an emotional saccade task. Cognitive, [Cogn Affect Behav Neurosci](#). 9, 314–322.

471 <https://doi.org/10.3758/CABN.9.3.314>

472 Xu, L., Ma, X., Zhao, W., Luo, L., Yao, S., Kendrick, K. M., 2015. Oxytocin enhances attentional

473 bias for neutral and positive expression faces in individuals with higher autistic traits.

474 Psychoneuroendocrinology. 62, 352–358. <https://doi.org/10.1016/j.psyneuen.2015.09.002>

475 Yao, S., Becker, B., Zhao, W., Zhao, Z., Kou, J., Ma, X., Geng, Y., Ren, P., Kendrick, K. M. (2018).

476 Oxytocin Modulates Attention Switching Between Interoceptive Signals and External Social

477 Cues. Neuropsychopharmacology. 43, 294-301. doi: [10.1038/npp.2017.189](https://doi.org/10.1038/npp.2017.189)

478

479 **Table 1** Questionnaire scores in PLC and OXT groups before and after treatment

Measurements	PLC	OXT	<i>t-value</i>	<i>p-value</i>
Before treatment				
Positive and Negative Affect Schedule (PANAS)				
Positive	27.97±0.83	27.82±0.99	0.12	0.91
Negative	16.22±0.92	15.91±0.85	0.24	0.81
State-Trait Anxiety Inventory (STAI)				
State	37.84±1.44	37.38±1.56	0.22	0.83
Trait	40.41±1.32	39.38±1.32	0.55	0.59
Liebowitz Social Anxiety Scale (LSAS)				
Avoid	24.35±2.20	20.21±1.99	1.39	0.17
Fear	25.89±2.32	22.35±2.27	1.09	0.28
Beck Depression Inventory (BDI-II)				
	7.03±1.00	6.41±1.06	0.42	0.67
Adult Autism Spectrum Quotient (ASQ)				
	21.30±0.85	21.88±0.96	-0.46	0.65
Childhood Trauma Questionnaire (CTQ)				
	40.16±1.38	39.88±1.17	0.15	0.88
Social Interaction Anxiety Scale (SIAS)				
	55.24±2.39	50.21±2.34	1.50	0.14
Behavioral Inhibition/Activation System Scale (BIS/BAS)				
BAS - Reward Responsiveness	6.97±0.30	6.91±0.30	0.16	0.87
BAS - Drive	7.76±0.22	7.94±0.35	-0.46	0.65

BAS - Fun Seeking	10.46±0.30	10.09±0.40	0.77	0.44
BIS - Behavioral inhibition	15.70±0.47	15.88±0.56	-0.26	0.80
Cognitive Emotion Regulation Questionnaire (CERQ)	47.16±1.03	46.69±1.36	0.29	0.77
Action Control Scale (ACS)				
Failure	5.24±0.47	6.00±0.61	-1.03	0.31
Decision	6.30±0.46	6.88±0.50	-0.88	0.38
Performance	9.05±0.27	8.69±0.34	0.88	0.38
After treatment				
Positive and Negative Affect Schedule (PANAS)				
Positive	22.97±1.13	22.71±1.41	0.15	0.88
Negative	12.78±0.69	12.24±0.58	0.60	0.55
State-Trait Anxiety Inventory (STAI) – State	37.64±1.37	34.17±1.30	1.84	0.07